CADILLAC â People in the Cadillac area engaged in an odd mix of activities Tuesday, when temperatures reached into the 50s while snow and ice still covered much of the landscape.
Residents wearing light jackets and in some cases even shorts and T-shirts walked their dogs, jogged, threw disc golf, and took their kids to the playground; all the while, ice fishermen dotted the frozen surface of Lake Cadillac in the background.
Travis Rebant and Luke Keway were playing the disc golf course at Kenwood Park. They both were enjoying the warmup after an extended period of being cooped up inside during the deepest parts of winter.
Banbury area community art exhibition - Hands Face Space Find Your Place - launches online this week banburyguardian.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from banburyguardian.co.uk Daily Mail and Mail on Sunday newspapers.
Exact Sciences Announces Fourth Quarter 2020 Results
News provided by
Share this article
Share this article
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging backdrop because of the pandemic, said Kevin Conroy, chairman and CEO of Exact Sciences. We are a leader in cancer diagnostics because of our people, scientific platform, and market-leading Cologuard and Oncotype tests. We aim to extend this leadership throughout the cancer continuum and bring additional tests to patients to help improve cancer outcomes.
/PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology.
Exact Sciences Announces Preliminary Fourth Quarter 2020 Results
- Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M
News provided by
Share this article
Share this article
MADISON, Wis., Jan. 10, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fourth quarter ended Dec. 31, 2020. I m incredibly proud of how the Exact Sciences team came together during 2020 to make progress towards our mission of eradicating cancer and the suffering it causes, said Kevin Conroy, chairman and CEO of Exact Sciences. Following our combination with Thrive, we are confident in making blood-based, multi-cancer screening a reality and being a leading provider of earlier, smarter cancer tests for patients at every step of their journey. We ve never been more excited abo